Literature DB >> 11021763

Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans.

E Arvat1, L Di Vito, F Broglio, M Papotti, G Muccioli, C Dieguez, F F Casanueva, R Deghenghi, F Camanni, E Ghigo.   

Abstract

An endogenous ligand for the GH secretagogue-receptor (GHS-R) has been recently purified from rat and human stomach and named Ghrelin. It has been demonstrated that Ghrelin specifically stimulates GH secretion from rat pituitary cells in culture as well as in rats in vivo. In this preliminary study, in 4 normal adults [age (mean+/-SE): 28.6+/-3.5 yr; body mass index (BMI): 22.3+/-2.1 kg/m2] we administered 1.0 microg/kg Ghrelin or GHRH-29 to compare their GH-releasing activities in humans. In all subjects Ghrelin induced a prompt, marked and long-lasting increase in circulating GH levels (peak: 107.9+/-26.1 microg/l; AUC: 6503.1+/-1632.7 microg/l/h). The GH response to Ghrelin was clearly higher (p<0.05) than that after GHRH (peak: 22.3+/-4.5 microg/l; AUC: 1517.5+/-338.4 microg/l/h). In conclusion, this preliminary study shows that Ghrelin exerts a strong stimulatory effect on GH secretion in humans releasing more GH than GHRH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021763     DOI: 10.1007/BF03343763

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  8 in total

Review 1.  Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation.

Authors:  C Dieguez; F F Casanueva
Journal:  Eur J Endocrinol       Date:  2000-05       Impact factor: 6.664

Review 2.  Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

Review 3.  Peptidomimetic regulation of growth hormone secretion.

Authors:  R G Smith; L H Van der Ploeg; A D Howard; S D Feighner; K Cheng; G J Hickey; M J Wyvratt; M H Fisher; R P Nargund; A A Patchett
Journal:  Endocr Rev       Date:  1997-10       Impact factor: 19.871

Review 4.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

Review 5.  Growth hormone-releasing peptides and the cardiovascular system.

Authors:  G Muccioli; F Broglio; M R Valetto; C Ghè; F Catapano; A Graziani; M Papotti; G Bisi; R Deghenghi; E Ghigo
Journal:  Ann Endocrinol (Paris)       Date:  2000-02       Impact factor: 2.478

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Authors:  E Ghigo; E Arvat; L Gianotti; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

8.  Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women.

Authors:  M C Gelato; O H Pescovitz; F Cassorla; D L Loriaux; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

  8 in total
  73 in total

1.  Ghrelin attenuates brain injury after traumatic brain injury and uncontrolled hemorrhagic shock in rats.

Authors:  Lei Qi; Xiaoxuan Cui; Weifeng Dong; Rafael Barrera; Jeffrey Nicastro; Gene F Coppa; Ping Wang; Rongqian Wu
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 2.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

4.  Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma.

Authors:  Marcus Mottershead; Emmanuel Karteris; Jill Y Barclay; Saira Suortamo; Mark Newbold; Harpal Randeva; Chuka U Nwokolo
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

Review 5.  Ghrelin: a new player in the control of gastrointestinal functions.

Authors:  T L Peeters
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

6.  Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.

Authors:  A Gambineri; U Pagotto; M Tschöp; V Vicennati; E Manicardi; A Carcello; M Cacciari; R De Iasio; R Pasquali
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

7.  Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans.

Authors:  A Benso; C Gottero; F Prodam; C Gauna; S Destefanis; L Filtri; A J van der Lely; R Deghenghi; E Ghigo; F Broglio
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

8.  Menopausal status influences the relationship between serum ghrelin levels and fat mass in healthy women.

Authors:  I Iwamoto; N Yoshimitsu; T Fujino; T Douchi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

9.  Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects.

Authors:  S Pöykkö; O Ukkola; H Kauma; M J Savolainen; Y A Kesäniemi
Journal:  Diabetologia       Date:  2003-03-14       Impact factor: 10.122

10.  Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis.

Authors:  Kavin G Shah; Rongqian Wu; Asha Jacob; Steven A Blau; Youxin Ji; Weifeng Dong; Corrado P Marini; Thanjavur S Ravikumar; Gene F Coppa; Ping Wang
Journal:  Mol Med       Date:  2009-09-18       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.